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Case presentation
A 15—year-old white male sought medical attention because his urine
became red following exercise. He was the product of a normal full-
term pregnancy; during the first 4 months his mother took Bendectin for
severe morning sickness. At birth he weighed 3444 g and was 52 cm
long; no physical abnormalities were noted, Subsequent growth and
development were normal. Childhood activities were not restricted by
symptoms or physician's order. At age 10 a physical examination
revealed no abaormalities.
Following a moderately strenuous teanis workout, he passed grossly
bloody urine for the first time. Physical examination a few hours later
revealed a normal-appearing adolescent male; he weighed 78 kg, was
188cm tall, and complained only of red urine. The only positive findings
were a blood pressure of 150/92 mm Hg and a slightly tender mass that
filled the right flank. Urinalysis revealed 4+ blood and 4+ protein;
sediment contained many red blood cells. A CT scan of the abdomen
showed bilaterally cystic kidneys with massive enlargement of the right
kidney, and a liver that was free of cysts (Fig. 1). A presumptive
diagnosis of nutosomal dominant polycystic kidney disease (ADPKD)
was made.
Serum creatinine ranged between 1.2 and 1.4 mg/dl. A radionucide
glomerular filtration rate (using MTc as a marker) was 136 ml/minll .73
m2, with 25% being derived from the right and 75% from the left kidney.
Gross hematuria gradually subsided and proteinuria disappeared.
Ultrasonographic examinations of the father, who is 38 years old,
disclosed single hepatic and right renal cysts; abdominal tiltrasono-
graphic examidation of the mother was normal. A detailed family
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history, encompassing the three most recent generations, is shown in
Fig. 2. Two paternal uncles suffered brain abscesses; one of these
uncles was described as having renal disease. No further instances of
proved or suspected ADPKD were recorded.
Discussion
DR. KENNETH D. GARDNER, JR. (Professor of Medicine,
University of New Mexico School of Medicine; Chief, Division
of Renal Diseases, University of New Mexico Hospital, Albu-
querque, New Mexico): Cystic diseases of the kidney are
common and costly, accounting for 10% of all end-stage renal
disease [1]. The current annual cost of their treatment in the
United States approximates $200 million. Research into their
causes and therapies has intensified in recent years. Although
these efforts have not yet isolated a common pathogenetic
mechanism or demonstrated a universally effective approach to
therapy, research has expanded our understanding and appre-
ciation of the disorders, Evidence now implicates genes, envi-
ronment, and intracorporeal conditions, very possibly working
ih concert, in the expression of renal cystic disease.
The young man whose story we have just heard is considered
by three independent nephrologists to have autosomal domi-
nant poiycystic kidney disease, a heritable, single-gene disorder
121. Abnormally compliant basement membrane has been sus-
pected as the abnormal gene product [1, 31. Yet our case
describes a young patient whose kidneys are not symmetrically
involved. His right kidney has many times the volume and
one-third the function of his left. His case is not unique. The
asynchronous expression of ADPKD is common [4, 5], occur-
ring in perhaps 20% of affected individuals [6]. But how can a
single gene disorder express itself to varying degrees in paired
organs unless other variables are involved?
The extent to which environmental factors or conditions
within the body might affect the expression of renal cystic
disease is a question that is of more than academic interest. If
truly significant nongenetic factors could be identified, their
modification might serve as bases for therapy in renal cystic
disorders.
Before I discuss clinical details relevant to the case, I will
review evidence that implicates not only heredity but also
environmental and local variables in the pathogenesis of renal
cysts, evidence that reflects the extent to which cystic kidneys
are made, not born. The evidence is voluminous and I consider
it persuasive. Terms relevant to my discussion are defined in
Table 1.
Genes and renal cystic disease
Some cystic kidneys and some renal cystic diseases clearly
are hereditary in nature, both in humans and animals; their
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Table 1. Terminology of renal cystic disease
Renal cyst
Cystic kidney
Renal cystic disease (RCD)
Acquired RCD
Induced RCD
Heritable RCD
Cystogen
An enclosed or communicating seg-
ment of nephron or duct that is di-
lated to a diameter of 200 microns or
more.
A kidney containing three or more
cysts.
Morbidity attributable to the presence
of renal cysts.
The spontaneous, idiopathic, bilateral
development of multiple cysts in
previously noncystic kidneys.
RCD produced by exposure to certain
drugs or chemicals.
RCD that presents within kindreds in
patterns predicted by mendeian the-
ory.
Agent capable of inducing renal cyst
formation or RCD.
Fig. 1. Enhanced abdominal CT scan of propositus. The right kidney is
enlarged (1409 cc) and massively cystic. The left kidney is normal sized
(148 cc) and displays two cysts at the level illustrated.
II
Ill
Fig. 2. Three most recent generations of propositus' family (squares:
male; circles: female). ADPKD has been diagnosed by three indepen-
dent nephrologists in the propositus and his father.
patterns are predicted by mendelian theory. The familial nature
of polycystic renal disease has been recognized since the early
twentieth century [7]. Recessive and dominant variants were
distinguished later [8, 9]. Experience with the nephronophthi-
sis-medullary cystic disease complex has been more recent but
similar [10, 11]. In animals, heritable polycystic renal disease
has been described in the mouse [12—14], rat [15], and springbok
[16] among others. A recent demonstration that ADPKD is
linked to markers on the short arm of human chromosome 16
[17, 18] provides the most definitive evidence yet available that
genetic misinformation predisposes to renal cyst development
and renal failure. As yet, however, no clues are available as to
the nature or action of the defective gene product.
Environment and renal cystic disease
Aberrant chromosomal material is not essential for the de-
velopment of renal cysts, as demonstrated by the occurrence of
both acquired and induced renal cystic disease. Acquired renal
cystic disease (ARCD) is exemplified best by the cysts that
develop in the kidneys of patients on chronic dialysis [19—22].
Whether ARCD has a counterpart elsewhere in nature is
speculative. Fish in the harbor of Hamilton, Ontario, display
renal cysts; researchers have suggested that these cysts are a
consequence of exposure to industrial pollutants in the water
[23].
Some 20 chemicals and drugs are known to induce renal cyst
formation [24]. Included among these "cystogens" are: diphe-
nylamine, diphenyithiazole, and nordihydroguaiaretic acid (all
antioxidants) [25—33]; alloxan and streptozotocin (diabetogenic
agents) [34, 35]; lithium chloride [36, 37]; and cis-platinum [38].
All these substances produce progressive renal cyst formation
in kidneys that orginally were noncystic and, presumably,
would have remained so had they not been exposed to the
cystogen. Aside from causing tubular cell injury [26, 30, 31],
these agents share no apparent common denominator. Their
administration, orally or parenterally as appropriate, is associ-
ated with progressive renal dysfunction that parallels the sever-
ity of morphologic change (Fig. 3). Thus they cause cystic
kidneys and renal cystic disease. Unlike AJDPKD, in which the
asynchronous or even unilateral development of cysts can
occur, cyst development in these models always is bilateral—a
fact that argues against the speculations of Darmady et al that
an endogenous cystogenic metabolite, analogous to these
agents, alone causes ADPKD in humans [26].
Environmental manipulation and renal cyst development
The renal changes that are produced by chemical cystogens
are not an all-or-none phenomenon. These alterations can be
influenced by environmental events [39]. The idea that heredi-
tary renal cystic disease is susceptible to environmental influ-
ences originated from observations made on the CFWwd mouse
[12, 39]. Approximately 70% of these animals develop renal
cystic disease when raised in the ambient laboratory environ-
ment. When maintained in a germ-free setting, however, virtu-
ally none of the animals develop disease.
Two laboratories have examined the relationship between
environment and the expression of chemically induced cystic
nephropathy. Kanwar and Carone demonstrated that continued
exposure to diphenylthiazole is necessary for this form of cystic
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FIg.3. Renal dysfunction correlates with renal pathology in chemically
induced renal cystic disease. Shown is the relationship between blood
urea nitrogen (BUN) and semi-quantitated evaluations of renal pathol-
ogy (pathology scores) [32, 33] in 28 conventional 180 g Sprague-
Dawley rats fed 2% NDGA for 6 wks [BUN = 3.62(PaSc) + 18,53].
disease to evolve in the rat [29]. If the agent is withdrawn, renal
cystic changes, unless advanced, regress.
Environmental manipulation also influences the cystogenicity
of nordihydroguaiaretic acid [32, 33]. Germ-free rats fed this
agent for as long as 42 days do not develop cysts, providing the
animals are maintained in a sterile environment (Fig. 4). They
do develop renal cysts, however, when fed the drug first in the
germ-free and then in the ambient laboratory environment [32]
or if, while taking the agent, they are maintained germ-free but
injected with endotoxin [33]. These maneuvers result in in-
creases in the numbers of circulating leukocytes and the devel-
opment of inflammatory infiltrates in the renal interstitium.
These changes, in turn, parallel the severity of renal cyst
development. The findings demonstrate the capability of envi-
ronmental events to dictate not only whether cysts form, but
also how rapidly they develop. Furthermore, in the absence of
consistent intrarenal infection (and given that leukocytosis and
interstitial inflammation correlate directly with nephron dilation
[33]), the data suggest that interstitial inflammation, occurring
in the absence of bacterial infection, is involved in the patho-
genesis of renal cysts. Considerable work remains to be done
before this hypothesis is confirmed or denied.
Intracorporeal conditions and renal cyst development
The idea that intracorporeal conditions influence the devel-
opment of renal cysts can be supported by several observa-
tions. One is the observation of asymmetric or unilateral
development of ADPKD. as in the patient under discussion
today [4—6]. A second is the phenomenon of the congenital,
unilateral multicystic kidney—a noninherited form of renal
dysplasia in which local obstruction to urinary outflow is
associated with development of cysts in approximately 90% of
cases [40]. A third is the observation that intrauterine ligation of
ureters in fetal rabbits causes renal cysts [41]. Fourth is the
dramatic demonstration that when cystic kidneys from cpk/cpk
mice are maintained in vitro, they revert completely to normal
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Fig. 4. Environment determines the cystogenicity of NDGA. Shown is
the effect of contamination (deconditioning) on the evolution of renal
pathology [32, 33] in NDGA-fed rats (solid circles). Twenty-three2.5 initially germ-free rats were fed NDGA for 14—21 days in isolators and
then moved to the ambient laboratory environment [33]. NDGA feeding
was continued for an additional 7—42 days. Their kidneys showed
changes that correlated with the duration of the contamination interval
[PaSc = 0.079(days) - 0.89]. In contrast, kidneys from 11 rats fed
NDGA for 14, 21, or 42 days in the germ-free setting showed no change
(left panel) and were identic4l in morphology to those of 5 germ-free
rats sacrificed after 21 days on normal diet (open circles).
[421. Fifth is the fact that cystic kidneys change size, often
becoming smaller, after dialysis or transplantation [43].
We explored the importance of local conditions on nephron
dilation and cyst formation in two limited, unpublished exper-
iments in rats. Eight weeks after a heated needle is touched
lengthwise to the kidney surface, nephrons adjacent to the
resulting scar dilate to 6 to 8 times the normal diameter.
Figure-eight ties made with a silk thread that is tightened
sufficiently to cause only slight indentation of the renal surface
also result 8 weeks later in the appearance of dilated nephrons
in areas adjacent to the ties. These results demonstrate that
physical insults, restricted to a local area of the kidney, have
the capability to induce dilation of nephrons.
Evidence for the mull jfactorial origin of cystic kidneys
The observations I have just described implicate three appar-
ently diverse insults in the pathogenesis of renal cyst formation.
Data indicating that the three—genes, environment, and local
and/or internal conditions—might interact in the development
of cystic kidneys are presented in Figure 5.
Characteristic features of cystic kidneys
Whether inherited, induced, or acquired, cystic kidneys are
remarkably heterogeneous. Unlike their normal counterparts,
these kidneys are not orderly, uniform, or symmetrical in
structure and function. Their structural disarray is readily
apparent on inspection and under low-power micrography (Fig.
6). Dilated tubules in varying numbers are interspersed among
tubules of normal diameter. Surface morphology of the epithe-
lium that lines the cysts often is atypical, and cell growth, as
evidenced by epithelial hyperplasia, is disordered (Table 2).
One of several forms can be identified: flat nonpolypoid hyper-
plasia, polypoid hyperplasia, or neoplastic proliferation [44].
Some micropolyps contain core vessels [44, 45], whereas others
appear as nothing more than a piling up of cells [45]. Whether
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Fig. 5. Schematic representation of the
multfactorial origins of renal cyst
INTERNAL MILIEU development. Given are examples of
Cystogenic effects of NDGA experimental data that support the individual
are absent in germ-free (rectangles) and interacting (circles)
setting. contributions of heredity, environment, and
ADPKD develops internal/local variables to the formation of
asynchronously/unilaterally, cysts in a susceptible kidney.
Fig. 6. Low-power photomicrograph of a cystic kidney fro,n a rat fed diphenylamine [27]. Massively cystic nephrons are interspersed among
nephrons of more normal diameters. Some cysts are filled with proteinaceous material; others are not. Hematoxylin and eosin stain (magnification
x25).
this difference in structure is significant has not been estab- lar basement membrane are evident on microscopic examina-
lished; either or both forms could represent sites of oncogene tion and chemical analysis [28, 29]. The basement membrane
expression or tumor development [39, 44]. Alterations in tubu- appears split and layered, particularly around cysts, and per-
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Table 2. Epithelial hyperplasia in some renal cystic diseases
Disease Hyperplasia? Micropolyps?
Human
Autosomal dominant PKD
Autosomal recessive PKD
Yes [45]
Yes"
Yes [451
Nob
Medullary cystic disease Yes [571 Yes [571
Von Hipple-Lindau disease Yes [58] Yes [58]
Tuberous sclerosis Yes [59] Yes [59]
Animal
cpk/cpk mouse Yes" Nob
Rat
Kitten (single specimen)
Yes [32, 33]
Yesb
Yes [32, 33]
Yes"
Pig (single specimen) Yes" Yes"
haps is the consequence of cyclical epithelial cell proliferation
and death [3, 26].
Diversity of function is evident in the greater-than-normal
variations that exist among both single-nephron glomerular
11 15 19 23 27 31 35 39 43 47
Pressure (cm water)
Fig. 8. Frequency plots of intraluminal hydrostatic pressures in 41
cystic (above) and in 27 normal rat nephrons (below). Pressures are
higher in cystic nephrons [27, 30, 31].
filtration rates and intraluminal hydrostatic pressures. Although
mean single-nephron GFR is virtually identical in cystic and
normal kidneys of rats, individual values vary to a significantly
greater degree in cystic kidneys [27, 30, 31] (Fig. 7).
Intraluminal hydrostatic pressure has been recorded in ani-
mals and in humans. In kidneys of rats with induced disease,
mean pressures are higher, and variability among values is
greater, in cystic than in normal tubules [27, 30, 31, 46] (Fig. 8).
Pressures are higher in the dilated than in the nondilated tubules
of kidneys scarred by searing and kidneys around which figure-
eight ties have been placed (Fig. 9). Only one study in humans
has attempted to measure intracystic pressures in vivo [47].
Widely variant pressures among and within kidneys were
recorded (Fig. 10).
Diversity extends to the content of cysts and the composition
of cyst fluid in the kidneys of patients with ADPKD [48, 49]
and, for the few examples that are available, of patients with
medullary cystic disease [11]. Cyst fluid can be clear to opaque
in lucency, and brown, white, or yellow in color. Sometimes it
is so viscous that it cannot be aspirated through a 14—gauge
needle (personal observation). Because concentrations of sol-
utes in cyst fluid vary widely, the possibility exists that cells
lining some cysts are metabolically active [48—50].
18.0
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6.0
0
33.0
22.0
11.0
0
7
a Numbers in brackets refer to references.
b Evan AP, Bernstein J, personal observation.
E0,
0)
Fig. 7. Frequency plots (percentages of all observations) of SNGFRs in
61 cortical nephrons of 21 kidneys from rats with induced renal cystic
disease (above) and in 41 nephrons from 10 norma! rat kidneys (below)
[27, 30, 31]. Although means (±SE) are similar (cystic: 40.3 1.9;
normal: 40.4 1.7 nI/mm), the degree of variation among values in
cystic kidneys is significantly greater than normal (0,05 > P < 0.25)
(Bartlett's test [85]).
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Fig. 9. Means (± SE) of intraluminal pressures in 4—7 dilated (DIL) and
4—8 nearby normal (NOR) cortical nephrons of 4 rats with seared
(R1—R4) and 3 rats with figure 8-tied (R5—R7) kidneys. Pressures are
significantly higher in dilated (cystic) nephrons of all rats but R2.
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Fig. 10. Pressures recorded in vivo in 14 human cystic kidneys (adapted
from Ref. 48). Variability is evident in both the means (5) and the
ranges (—) of pressures. Numbers in parenthesis refer to numbers of
cysts studied in each case.
Hypotheses of renal cyst development
Separate but not mutually exclusive hypotheses of renal cyst
formation have evolved from the experimental and clinical
observations I have described. Three of these theories are
presented in Figure 11. The first, which cites increased compli-
ance of tubular basement membrane as the primary defect [1],
is suggested by the altered structure and composition of the
tubular basement membrane [26, 28, 29]. In addition, the
increased incidence of hepatic and pancreatic cysts [51], cere-
bral aneurysms [51], colonic diverticulae [52], and mitral valve
prolapse [53] in patients with ADPKD suggests that the base-
ment membrane in extrarenal sites also is lax. The second
hypothesis, secretion, involves reversal of net water and solute
movement, that is, influx instead of efflux from the affected
nephrons. This theory has experimental support from at least
three observations. (1) Sodium-potassium ATPase appears to
mediate cyst formation in metanephric organ cultures [54]. (2)
The cyst wall taken from a polycystic kidney is metabolically
active and pharmacoresponsive in vitro [50]. (3) Cyst-like
structures are formed by standard MDCK cells when grown in
vitro in collagen gel [55, 56]. The third hypothesis implicates
epithelial hyperplasia, micropolyps [44], or both as a cause of
partial obstruction to tubular outflow [45, 57]. Dilation occurs
as the consequence of the increased intraluminal pressures [30,
31, 39, 45] that exist in these kidneys in vivo. In any or all of
these three as well as in a fourth hypothesis, the possibility that
cell transformation, somatic mutation, oncogene expression
[39, 44], and/or genetic predisposition occur can be incorpo-
rated. The fourth hypothesis is referred to as the "prolifera-
tion" hypothesis and views cysts as being formed because of
abnormal outward cell growth [3]. Support for this postulate
comes from the cellular hyperplasia found in animal models of
cystic disease and the polyps and tumors found in human cystic
renal disease [27, 31—33, 39, 44, 57—59].
Each of these hypotheses has recognized shortcomings.
Similar, instead of disparate, intraluminal hydrostatic pressures
should exist among cysts and tubules within a cystic kidney if
interstitium and basement membrane offer no resistance to
dilation. To the contrary, five- to tenfold differences in pressure
can be found in a single kidney (Figs. 8 and 10); thus a barrier
to the transmission of pressure is present around individual
cysts and dilated nephrons. Furthermore, the deformability of
tubular basement membranes from cystic kidneys, as measured
in vitro, is the same as that from normal nephrons [60]. Net
inward movement of water and solute has not been demon-
strated in human cystic kidneys. Cyst walls mounted in Ussing
chambers exhibit outward, not inward, active transport char-
acteristics [50]. The obstruction hypothesis is faulted for its
failure to adequately explain how relatively noncompliant base-
ment membrane becomes deformed [3]. The neoplastic origin of
renal cystic disease has been considered and dismissed [61]. It
does not explain how some pressures become elevated. Out-
ward growth of proliferating cells in itself would not cause
elevation of intraluminal pressures. Further, outward growth
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Table 3. Signs and symptoms of renal cystic disease
Abdominal swelling
Abdominal or flank mass(es)
Pain in flank or abdomen
Ureteral colic (with stone or clot)
Recurring urinary tract infections
Hypertension
Rising hematocrit and/or hemoglobin
Gross or microscopic hematuria
Progressive renal failure (azotemia)
Nephrocalcinosis
Anuria (rare)
Proteinuria less than 3 g per day
seems an unlikely event if it must occur against resistance
mounted by adjacent basement membranes and interstitium,
and in the presence of tubules and cysts with elevated pres-
sures.
What, then, causes cysts to form in the kidney and the cystic
kidney to fail? In my judgment, the obstruction hypothesis
remains the most likely. It explains how pressures become
elevated in nephrons with relatively greater degrees of resis-
tance to outflow as a consequence of cellular hyperplasia,
micropolyp formation, increased fluid viscosity, scarring, and/
or compression. It incorporates the conclusion derived from
clinical experience that enlarging cysts compress adjacent nor-
mal renal tissue and cause renal failure [621. It helps explain
why cyst decompression might be an effective form of therapy
in ADPKD [63]. I'll return to this issue later.
Clinical man(festations of cystic kidneys
Whatever their pathogenesis, cystic kidneys do not always
produce overt disease. Kidneys with simple cysts frequently
are asymptomatic [64]. In contrast, acquired renal cystic dis-
ease (via cystic rupture or malignant change) [19—22], and
ADPKD [51] and medullary cystic disease (via progressive
renal failure) [10, 11] are commonly life-threatening illnesses.
Cystic kidneys can be discovered fortuitously or they can
present with one or more of the symptoms and signs listed in
Table 3. A patient who has a positive family history or who is
undergoing chronic dialysis is predisposed to cystic disease. In
patients with ADPKD, abdominal or flank masses, hematuria,
pain, hypertension, and recurring urinary tract infections are
the most common forms of presentation [6, 9, 39, 52, 62].
Whether hypertension or infection play roles in the pathogen-
esis or progression of renal failure is not established. For
acquired renal cystic disease, pain and hematuria are typical.
The spontaneous onset of shock and prostration (owing to cyst
rupture) is less frequent but also characteristic [19—22].
Detection of cystic kidneys
Criteria for the diagnosis of renal cystic disease need to be
applied stringently. The diagnosis requires the presence of
multiple cysts (3 or more) and demonstrable morbidity from, or
impainnent of renal function in, the involved kidney(s) (Table
1).
Ultrasonography and computerized tomographic scanning
with or without contrast media are the most useful detection
techniques at present [65]. Each is capable of detecting renal
cysts of 0.5 cm or less in diameter [66]. The likelihood of
overlooking cysts is significantly reduced when both ultraso-
nography and CT scanning are performed, particularly when
cysts are small or few in number [65—67]. The probability that
one can have ADPKD despite normal results by ultrasonogra-
phy declines with age for persons who are at 50% risk, and is
estimated at 0.14 in the third decade of life [68]. Nuclear
magnetic imaging offers promise [69, 70], but experience with it
in patients with cystic kidneys is limited.
Intravenous urography no longer is recommended for the
routine demonstration of renal cysts, given its relatively lower
sensitivity and its risk, albeit small, of contrast-induced renal
failure [71]. Retrograde pyelography should be avoided because
it cArries an increased risk of infection in the patient with cystic
kidneys [39].
Therapy: The case revisited
The diagnosis of ADPKD in the patient under discussion here
was based on the presence of bilateral multiple renal cysts and
hypertension, and was supported by the discovery of single
hepatic and renal cysts in the father. Had the father been free of
cysts, a negative family history would not have precluded the
diagnosis. One-quarter of newly documented cases have no
family history of ADPKD; this figure has remalned unchanged
for 25 years [39, 62, 721. These apparently "spontaneous" cases
might represent mutations or erroneous diagnoses. They might
reflect nongenetic events that have caused expression of heri-
table disease. Or they might reflect acquired disease.
Because the pathogenesis of ADPKD is poorly understood,
therapeutic approaches often are based on speculation about
the mechanisms of cyst formation and growth. Cyst decompres-
sion, the Rovsing procedure, is a case in point. Cyst decom-
pression would seem an eminently reasonable means for reliev-
ing pressure on adjacent renal tissue—if it were agreed that
elevated pressures were present and were the cause of renal
failure in ADPKD. There is no such agreement [73]. Nonethe-
less, the Rovsing procedure, faulted on the basis of results in 2
patients in 1957 [74], recently has been revived. Bennett et al
treated 11 patients with refractory pain due to ADPKD by
percutaneous cyst aspiration or open surgical reduction [63].
All the patients experienced dramatic relief of pain and no
deleterious effect on renal function. This experience indicates
that additiontl, equally careful evaluations of cyst decompres-
sion in ADPItD are warranted.
Families often are anxious to know the implications of a
diagnosis of heritable renal cystic disease. The question of
whether to search for renal disease in an asymptomatic, at-risk
youngster provokes polarized responses. Serious doubt exists
relative to the future insurability, marriageability, and employ-
ability of such an individual. Because of these issues, some
physicians discourage efforts at establishing an early diagnosis.
Conversely, others argue that early diagnosis permits early
detection and treatment of hypertension, silent urinary tract
infection, or malignancy if they occur. Protagonists of this
position encourage diagnosis at the earliest age possible.
The bioethical debate surrounding the early diagnosis of
untreatable renal cystic disease and other inherited disorders
has just begun [75, 76]. In our patient the issue was moot. He
was symptomatic, and the search for the cause of his hematuria
was obligatory. Diagnostic studies were performed on the
parents at their requests, even though they knew that little,
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other than monitoring, could be done if disease were discov-
ered.
Two forms of experimental therapy were discussed with the
propositus and his family. The first, amiloride administration,
has not been proved efficacious. The potential differences
generated across cyst walls in vitro are responsive to the
inhibitory effects of amiloride [50, 56]. On the possibility that
active transport occurs into cysts, the propositus was offered
the opportunity to take this drug as a means of retarding cyst
growth and subsequent renal failure, but the patient declined.
Cyst puncture and deroofing was the second procedure dis-
cussed [63]. This option remains under consideration by the
family. Had hematuria become life-threatening, focal emboliza-
tion or nephrectomy might have been considered.
Questions and answers
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital,
Chicago, Illinois): Why do cysts appear to form more readily in
the kidney than in other organs in patients with ADPKD?
DR. GARDNER: There is no evidence that cysts form more
readily in kidneys than in other organs. Up to the present, a
diagnosis of ADPKD has required that multiple bilateral renal
cysts be present. If there are no renal cysts, there can be no
polycystic disease. Consequently, all patients with ADPKD
have renal cysts, and an impression is created that cysts must
always develop in ADPKD.
The advent of genetic testing very likely will alter this
situation. The linkage studies of Reeders et al defined chromo-
somal markers that associate themselves with clinical ADPKD
[181. These markers do not identify the defective gene, but they
do provide a clue to its location. Armed with this information
and given today's technology, it should not take investigators
too long to identify the mutant gene and to determine its
structure. Once structure of the mutant gene is known, it will be
possible to identify its carriers and establish whether its pres-
ence is always or only sometimes accompanied by renal cyst
development. For now, however, we must still depend on the
appearance of renal cysts for diagnosis and carrier identifica-
tion.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital, Chicago): You noted that amiloride
can inhibit inward movement of fluid across cyst walls in vitro,
and you suggested a possible therapeutic role for this agent. Is
there any clinical experience to suggest that amiloride does
have a beneficial effect in patients with polycystic kidney
disease?
DR. GARDNER: There have been no studies in ADPKD
showing an effect of this agent on either cyst size or on the
progression of renal failure. I am told that experimental studies
are in progress.
DR. SATISH KUMAR (Fellow, Joint Michael Reese/University
of Chicago Nephrology Program): At what age should patients
with polycystic kidneys have their children screened for this
disease?
DR. GARDNER: Your question strikes at the heart of a
bioethical controversy. We have the tools with which to diag-
nose ADPKD relatively early in life. But when should we use
them? The answer is a matter of opinion. No set standards
exist. Age is one parameter to consider. Symptoms or signs that
necessitate medical evaluation, and the desires of the patient
and family to pursue or not pursue diagnosis are others.
Autosomal dominant polycystic kidney disease is a late-
onset, dominantly inherited, fundamentally untreatable disor-
der linked to known chromosomal markers. In these character-
istics it is similar to Huntington's disease. Geneticists involved
with that disorder have advised that only individuals 18 years of
age or older be tested unless unusual circumstances are present.
I think this advice is prudent. The asymptomatic child at risk for
ADPKD, in my opinion, should not be tested. Standards of
good medical practice dictate, as they did in our case, what to
do with the symptomatic individual irrespective of chronologic
age.
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pital): You mentioned that patients with ADPKD have a high
incidence of hypertension and that hypertension occurs even
when renal function is normal and hyperreninemia is absent.
This observation has always interested me because women with
ADPKD during pregnancy seem to have a higher incidence of
pre-eclampsia even when renal function is normal. On the other
hand, sisters of such individuals, who do not have the auto-
somal dominant disease, do not have an increased incidence of
pre-eclampsia [77].
DR. GARDNER: So little is known about hypertension's role in
the expression of ADPKD that any meaningful comment is
difficult. At one time hyperreninemia was thought to be respon-
sible for the hypertension that so commonly occurs in the
disorder. A recent study indicates it is not; instead, volume
appears to be the critical variable [78]. It seems wise to treat
high blood pressure in the patient with ADPKD, not in hopes of
slowing the progression to renal failure, but rather to avoid the
known, usual complications of arterial hypertension. Should
studies now underway at Colorado and elsewhere indicate a
beneficial effect of therapy on progression to renal failure, we
will come out ahead in the game.
DR. JOSHUA BAILIN (Renal Division, Michael Reese Hospi-
tal): Did you consider evaluating this young man for a berry
aneurysm, especially in light of his family history of supposed
brain abscesses? Would you consider such an evaluation in all
patients with polycystic disease?
DR. GARDNER: Your question is frequently asked by those
who must diagnose and care for patients with ADPKD. Patients
with ADPKD have an increased risk of associated intracranial
aneurysm and possibly of death from intracranial hemorrhage.
However, few physicians recommend routine cerebral angiog-
raphy. Even fewer recommend prophylactic surgery in asymp-
tomatic individuals. None of the nephrologists consulted by our
patient has advised that he be screened.
Levey, Pauker, and Kassirer utilized decision analysis to gain
some insight into when the benefits of a search for an aneurysm
might outweigh the costs and dangers [79], Their analysis
showed that the benefit of arteriography was marginal for most
patients.
One critical piece of information that would make the analy-
sis by Levey, Pauker, and Kassirer more meaningful and your
question an easier one to answer is not available. We have no
idea of the frequency of cerebral aneurysm in the general
population [80]. Thus, we do not know whether the incidence in
ADPKD is increased or not. Until some test, less invasive and
expensive than cerebral angiography, is available for routine
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screening of patients with ADPKD and the general public, we
will not know. At present, I do not perform routine cerebral
angiography on my patients with asymptomatic ADPKD.
DR. JAMES BOURDEAU (Renal Division, Michael Reese Hos-
pital): Are urinary tract infections more difficult to eradicate in
patients with polycystic kidneys? If so, are there specific
therapeutic strategies that you recommend?
DR. GARDNER: A figure for the incidence of urinary tract
infection in ADPKD is not available. Some data suggest that it
is relatively common. Dalgaard noted that pyuria, bacteriuria,
and symptomatic urinary infections occurred in over 60% of
persons with ADPKD at some time during the course of their
disease [62]. We have commented on the frequency of infection
and its possible role in the evolution of renal failure [39]. In the
presence of cystic kidneys, urinary tract infection is potentially
dangerous. When it spreads to the kidney, it can be difficult to
control.
Most frequently the offending organism is E. coli. In cases of
suspected urinary tract or renal infection, one should culture
urine, blood, and cyst fluid if the opportunity presents. Culture
results dictate initial therapy. If cultures are sterile, penicillin or
an aminoglycoside can be tried. In the absence of a response, if
the clinical condition deteriorates, or if it initially is life-
threatening, lipophiic antibiotics are the agents of choice [81].
They seem to readily enter most cysts, in contrast to other
antibiotics, which gain access preferentially to the so-called
"proximal" or less acidic cysts. Schwab has advised that
chloramphenicol be used [81].
DR. BOURDEAU: From which segments of the nephron are the
cysts derived? If they originate from more than one segment,
would that imply several discrete developmental abnormalities?
DR. GARDNER: Cysts derive from all segments of the neph-
ron. Microdissection studies show that the collecting segments
and loops of Henle are the more common sites [1]. Proximal
tubules and even glomerular capsules also are frequently in-
volved. No comparative study has been conducted with the
idea in mind that cysts might derive from a specific, different
segment of the nephron in each of the different renal cystic
diseases, Microscopically, they do not appear to do so, but the
epithelial lining of most cysts is nondescript and therefore is of
no help in defining the tubular origin of any single cyst [82].
DR. SE1tnNo GARELLA (Associate Chairman, Department
of Medicine, Michael Reese Hospital): There are circumstances
in which knowing whether a given patient has an acquired or
hereditary form of polycystic kidney disease is clinically impor-
tant. What guidelines do you recommend for making this
distinction? For example, let us assume that one sees a patient
similar to the one described here, who develops end-stage renal
failure and in whom one cannot verify a family history of
polycystic kidney disease. if the issue of transplantation from a
living-related donor comes up, do you rely on the likelihood
that renal failure occurs at about the same age in members of
the same family? And, at what age do the various diagnostic
tests that you have enumerated become sensitive enough to
allow you to select a younger family member as a donor? How
available, sensitive, and specific is chromosome analysis, and
when would you perform such an analysis to help you in the
decision?
DR. GARDNER: Confusion between polycystic and acquired
cystic disease can arise. Criteria that help make the distinction
have been reviewed [83]. The kidney of polycystic kidney
disease tends to be large, palable, diffusely cystic, and irregular
in contour, whereas the kidney of acquired cystic disease tends
to be normal-sized, non-palpable, focally cystic, and smooth in
contour. Cysts tend to be larger and more variable in size in the
kidney of polycystic disease than in that of acquired cystic
disease. Adenomas occur in 25% of the latter but are rare in the
former. The history usually is positive for familial involvement
in ADPKD. Differentiation of medullary from acquired cystic
disease can be more difficult because kidneys are smallish and
cysts can be sparse in both. Biopsy may be necessary; doubt
can remain.
Donor selection for kidney transplantation sometimes con-
founds even the best of us. I suppose the best policy is one that
dictates "when in doubt, use another kidney," but such a
course of action is not always practicable. I no longer rely on a
family's mean age at onset of renal failure as a criterion for
donor selection. Dalgaard documented the tendency for ages at
onset of renal failure to remain fairly constant from generation
to generation within a kindred [62]. Several nephrologists whom
I respect have challenged that concept recently, citing their own
experiences and the fact that Dalgaard was dealing largely with
autopsy material and clinical diagnoses based on pyelographic
findings, both of which tend to miss early lesions.
Current practice utilizes ultrasound and CT scanning in
evaluation of the potential donor who is at risk for hereditary
renal cystic disease. If neither test detects cysts in kidney or
liver, and if the prospective donor is over 30 years of age, it
probably is safe to proceed with kidney donation. There is good
evidence that cysts, if they are ever going to develop, will be
visible by that age [68]. The younger the age below 30 years,
however, the greater the possibility of normal results in an
individual destined to develop disease.
We have little experience to date with chromosomal analysis
in donor selection. The technique is not infallible. It employs
markers on chromosome 16 that are close to, but are not
themselves, the mutated gene. Because DNA can sometimes
break between marker and gene, it is possible for a person to
possess the marker without the gene or vice versa. Wrong
conclusions can be drawn.
DR. GARY TOnACK (Renal Section, Mitchell Hospital): The
kidneys of patients with end-stage disease often exhibit tubular
cell proliferation prior to treatment by chronic hemodialysis,
and renal cysts and occasionally cystadenocarcinomas appear
in the diseased organ when life is prolonged by dialysis. Do you
think there is a common mechanism that mediates cyst forma-
tion both in patients with end-stage renal disease and in subjects
who develop cysts when renal function is normal? Do you think
specific factors associated with treatment of end-stage renal
disease predispose to the formation of renal cysts?
DR. GARDNER: I will indulge in a little speculation. I do
suspect that a common mechanism underlies cyst formation in
the normal and the end-stage kidney: epithelial hyperplasia,
acting to produce partial but not complete obstruction of
functioning tubules. The extent of disordered cell growth in
cystic kidneys is impressive. Also impressive to me is the
frequency with which tumors and cysts in the kidneys are
associated, with or without renal failure [39]. I think obstruction
best explains the association, as I discussed earlier. The key
questions that follow are: Why does hyperplasia occur? What
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sets it off? Is it a normal or an abnormal response? The idea of
a nephrotoxic substance [261, the product of an inborn error of
metabolism in the case of inherited disease or of uremic
metabolism in the case of acquired disease, is an attractive one,
as I mentioned, but no such substance has been found. Perhaps
we have not looked long enough or hard enough for it. Perhaps
it is a "normal" metabolic product that goes unrecognized
because we expect it when we find it.
In the case of human acquired disease, prolongation of the
normal aging process might favor cyst development. Someone
once referred to the kidneys of dialysis patients as "post-
stygian," kidneys that have crossed over the River Styx and
lived beyond their time. "Post-stygian" kidneys are character-
ized by vascular sclerosis, cyst formation, epithelial proliferation,
disordered cell growth, polyps, adenomas, and malignancies.
Experience in the laboratory indicates that we can produce
renal cysts at will by causing tubular cell injury and that the
severity of the resulting lesion depends on the intensities of the
systemic and local responses. It is my guess that the mystery of
renal cyst formation—massive nephron dilation if one likes—
will be solved when we develop a better understanding of
injury-response mechanisms in the kidney.
DR. TOBACK: Do the mice that exhibit hereditary renal cyst
formation also develop cysts in the liver?
DR. GARDNER: The cpk/cpk mouse [13], the mouse reported
from Japan [14], and a pig model have cystic livers as well as
cystic kidneys.
DR. TOBACK: Has the biology of renal cysts been studied in
vitro by setting up organ cultures from mice with hereditary
renal cystic disease?
DR. GARDNER: Kidneys from the cpk/cpk mouse have been
studied in vitro by Avner, who has done a series of what I
consider to be very elegant experiments. I referred to the
results of one in my discussion: the cystic kidneys of fetal
cpk/cpk mice revert to normal when excised and maintained in
vitro [41].
DR. PAUL SACKS (Renal Fellow, Michael Reese Hospital): In
view of the high incidence of acquired cystic disease in our
patients with end-stage renal disease and the potential for
neoplastic change, what guidelines do you recommend for
following the asymptomatic patient for development of malig-
nancies?
DR. GARDNER: I advocate ultrasonography of all dialysis
patients on an annual or biannual basis, with CT scanning to
follow in those individuals found to have cysts [39]. If CT
scanning suggests tumors larger than 2 cm in diameter, I
advocate nephrectomy. Similar recommendations have been
made by others [191. The pragmatics of the real world have kept
us from acting on these guidelines, however; the cost of such
surveys of the dialysis population evidently is considered
prohibitive by third-party payers. Consequently I, as I suppose
most of you have done, have settled for prompt evaluation of
the symptomatic patient. I perform ultrasonography on any
patient with end-stage renal disease who has hematuria, pain,
shock, urinary tract infection, or otherwise unexplained fever in
a search for acquired cystic disease. Subsequent CT scanning
and renal arteriography are performed as indicated by ultraso-
nographic results. At my institution we have encountered no
reluctance from third-party payers to cover the costs of these
studies when symptoms are present.
DR. COHEN: In your experience, do patients on chronic
dialysis who develop acquired cystic disease have a reduced
transfusion requirement? If so, is this change a useful clue to
the presence of the disease in this population?
DR. GARDNER: Reduced transfusion requirement is not a
situation that I have seen first-hand. Rising hemoglobin, that is,
reversal of the chronic anemia of renal failure, has been
considered a helpful sign of acquired renal cystic disease [84]. It
occurs in some but not all patients.
DR. GARELLA: Your data showed two major peaks in the
range of sodium concentration in the cyst fluid: at one extreme,
the cyst-to-plasma sodium concentration ratio was approxi-
mately 1.0, and at the other, it was approximately 0.1. I
presume that the osmolality of the cyst fluid is indistinguishable
from that of plasma. If the sodium concentration can reach such
low values, what is the solute that substitutes for sodium?
DR. GARDNER: Amino acids are the culprit! They achieve
concentrations as high as 50 millimolar in some low-sodium
cysts [50, 74]. The patterns of their distribution are not consist-
ent from cyst to cyst and they appear not to conform with
expected patterns if a given tubular transport mechanism for
amino acids were at fault or if tubular proteases were splitting
filtered albumin inside the cysts [50].
Cyst fluid tends to be isosmotic to the plasma of the well-
dialyzed patient (278—283 mOsm/kg water). Differences among
cysts within the same kidney, however, are as great as S
mOsm/kg water—a difference that probably reflects variability
in technique but which, on the other hand, may be real. If
present in vivo, a 5 mOsm osmotic gradient could be a major
determinant of cyst size. At present, the origins of intracystic
amino acids and the impact of their osmotic activity on cyst
growth remain two of the undefined mysteries of ADPKD.
DR. COHEN: One of the hypotheses you mentioned to explain
cyst formation is intratubular obstruction, perhaps from luminal
encroachment by proliferating epithelial cells. But you ex-
pressed doubt about this hypothesis because the measured
compliance of the basement membranes seemed to be such that
greater hydrostatic pressures within the cyst would be required
than are actually observed. Is it not possible, however, that
time is an important variable in this regard? That is, couldn't
pressures of the magnitude that are found, if exerted over
months and years, cause eventual distention of the basement
membrane even if such pressures, when applied acutely in the
experimental setting, do not?
DR. GARDNER: I think that they could. The in-vitro study of
basement membrane compliance was indeed acute and short-
term [60]. Even though no differences in compliance were found
in that study, its results left some room for argument. Based on
its data, calculations were made of the transmural pressures
required to distend basement membrane. These derived values
are higher than most, but not all, intracystic pressures mea-
sured in vivo [60] (Figs. 8 and 10). With due respect to
theoretical argument, then, I continue to think that increased
pressures contribute to renal cyst enlargement, because ele-
vated pressures are found in so many cystic kidneys.
I am willing to consider other mechanisms of cyst growth. In
the germ-free rat model studied in our laboratory, cysts develop
rapidly (within 21 days) in the kidneys of deconditioned or
endotoxin-injected germ-free rats fed nordihydroguaiaretic acid
[32, 33]. Andy Evan and I are struck by the proximity of
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neutrophils, as well as lymphocytes and macrophages, to cysts
and to foci of epithelial hyperplasia in these kidneys. Some of
these inflammatory cells can be seen apparently leaving vessels
and interstitium and entering the walls and lumina of tubules
and cysts. These migrating cells must make holes in the walls as
they pass through them. The holes must be closed, presumably
by new cells and new basement membrane. Perhaps cysts
develop from cycles of such injury and repair, a process that is
directed outward because hydrostatic pressures are higher
inside tubules.
DR. TOBACK: Do you mean to imply that the receptor for the
leukocytes might be an abnormal basement membrane constit-
uent?
DR. GARDNER: It might. Primary injury to tubular cells, as we
have discussed, is a second possibility [26], Not all cystic
kidneys show interstitial inflammation. None does so to the
degree observed in our model. But none develops cysts as
rapidly s does the model, either. The role of interstitial events
in the development of chronic renal disease is a topic of current
interest in nephrology. If one accepts the facts that cysts are
massively dilated nephrons and that dilated nephrons are found
in many of the chronic interstitial nephritides, then it is not such
a big jump to suspect and search for a pathogenetic relationship
between the two in renal cystic disease. While we wait for the
results of studies addressing this issue, we also can wait to see
whether cysts develop in normal kidneys transplanted into
patients with ADPKD. If cysts do develop, a search for the
circulating renal cystogen will begin in earnest. If they do not, we
will have to find other explanations for renal cyst development.
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